Role of neutrophil-specific NOX2 in alcohol-induced liver injury
中性粒细胞特异性NOX2在酒精性肝损伤中的作用
基本信息
- 批准号:10621545
- 负责人:
- 金额:$ 43.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAdoptive TransferAdrenal Cortex HormonesAffectAgonistAlcoholic HepatitisAlcoholic Liver CirrhosisAlcoholic Liver DiseasesAlcoholsAttenuatedCellsCessation of lifeChronicDataDefectDevelopmentDiseaseEthanolExhibitsGoalsImpairmentInfectionInflammasomeInflammationInflammatoryInflammatory ResponseKnowledgeLiverLiver CirrhosisMacrophageMitochondriaModelingMolecularMusNADPH OxidaseNational Institute on Alcohol Abuse and AlcoholismPathogenesisPathway interactionsPatientsPentoxifyllinePersonsPharmacologic SubstancePhasePhenotypePlayPredispositionProductionReactive Oxygen SpeciesResolutionRoleSerine ProteaseSourceeffective therapyinflammatory markerinsightliver inflammationliver injuryliver transplantationmolecular markerneutrophilnoveltherapeutic developmenttherapeutic target
项目摘要
PROJECT SUMMARY
The goal of this proposal is to define the role of neutrophil-specific NADPH oxidase 2 (NOX2) in alcoholic
liver
disease(ALD) and to evaluate its potential as a therapeutic target. ALD affectsmore than 10 million people in
the U.S. and accounts for nearly half of liver cirrhosis-associated deaths. Understanding the pathogenesis of
ALD is imperative for the development of effective therapies. Neutrophil accumulation in the liver is a hallmark
for ALD. Evidence suggests that neutrophils are a key contributor to ALD. However, better understanding of
molecular pathways important in regulating neutrophil functions is required to target these cells for ALD
treatment. It is recently revealed that the activity and expression levels of NADPH oxidase (NOX)2, a major
source of reactive oxygen species (ROS), were dramatically reduced in neutrophils from patients with
advanced alcoholic cirrhosis or alcoholic hepatitis. Although ROS has been associated with inflammation,
mounting evidence also suggests that NOX2-derived ROS actually plays a critical role in limiting, rather than
promoting, inflammatory responses. Given the paradoxical role of NOX2, this proposal aims to fill the
knowledge gaps regarding whether and how NOX2 regulates neutrophil functions.
Our preliminary data demonstrate that mice with neutrophil-specific deletion of NOX2 develop exacerbated
liver injury and prolonged inflammation after chronic plus binge ethanol treatment. NOX2-deficient neutrophils
release much higher levels of IL-1 than WT-neutrophils. Together these findings led to our hypothesis that
neutrophil-specific NOX2 plays a critical role in limiting inflammation and promoting resolution of
inflammation during ALD. We propose three Specific Aims to (1) elucidate the mechanism accounting for
increased IL-1 production by NOX2-deficient neutrophils during ALD, (2) investigate the role of neutrophil-
specific NOX2 in the resolution of inflammation during ALD, (3) evaluate the potential of targeting neutrophil-
specific NOX2 to treat ALD.
项目摘要
本提案的目的是确定嗜中性粒细胞特异性NADPH氧化酶2(NOX 2)在酒精性
肝
疾病(ALD),并评估其作为治疗靶点的潜力。ALD影响超过1000万人,
在美国,几乎一半的肝硬化相关死亡病例都是由它引起的。了解其发病机制
ALD对于开发有效的治疗方法至关重要。肝脏中的神经递质积累是
对于ALD。有证据表明,中性粒细胞是酒精性肝脏病的关键因素。然而,更好地了解
需要在调节中性粒细胞功能中重要的分子途径来靶向这些细胞用于ALD
治疗最近发现,NADPH氧化酶(NOX)2的活性和表达水平,
活性氧(ROS)的来源,显着减少患者的中性粒细胞
晚期酒精性肝硬化或酒精性肝炎。虽然ROS与炎症有关,
越来越多的证据还表明,NOX 2衍生的ROS实际上在限制,而不是
促进炎症反应。考虑到NOX 2的矛盾作用,该提案旨在填补
关于NOX 2是否以及如何调节中性粒细胞功能的知识空白。
我们的初步数据表明,具有嗜中性粒细胞特异性NOX 2缺失的小鼠发生恶化,
慢性加酒精治疗后肝损伤和长期炎症。NOX 2缺陷型中性粒细胞
比WT-中性粒细胞释放更高水平的IL-1 β。这些发现共同导致了我们的假设,
嗜中性粒细胞特异性NOX 2在限制炎症和促进炎症消退中起着关键作用。
ALD期间的炎症。我们提出了三个具体目标:(1)阐明解释
在ALD过程中,NOX 2缺陷型中性粒细胞产生的IL-1 β增加,(2)研究中性粒细胞在ALD中的作用,
特异性NOX 2在ALD期间炎症消退中的作用,(3)评估靶向中性粒细胞的潜力-
特异性NOX 2来治疗ALD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cynthia Ju其他文献
Cynthia Ju的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cynthia Ju', 18)}}的其他基金
Role of chitinase-3-like-1 (Chi3l1) in acetaminophen-induced liver injury
几丁质酶 3-like-1 (Chi3l1) 在对乙酰氨基酚诱导的肝损伤中的作用
- 批准号:
10674986 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Role of Eosinophils in Hepatic Ischemia Reperfusion Injury
嗜酸性粒细胞在肝缺血再灌注损伤中的作用
- 批准号:
10365939 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Role of chitinase-3-like-1 (Chi3l1) in acetaminophen-induced liver injury
几丁质酶 3-like-1 (Chi3l1) 在对乙酰氨基酚诱导的肝损伤中的作用
- 批准号:
9898894 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Role of chitinase-3-like-1 (Chi3l1) in acetaminophen-induced liver injury
几丁质酶 3-like-1 (Chi3l1) 在对乙酰氨基酚诱导的肝损伤中的作用
- 批准号:
10464890 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Role of Eosinophils in Hepatic Ischemia Reperfusion Injury
嗜酸性粒细胞在肝缺血再灌注损伤中的作用
- 批准号:
10658011 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Role of chitinase-3-like-1 (Chi3l1) in acetaminophen-induced liver injury
几丁质酶 3-like-1 (Chi3l1) 在对乙酰氨基酚诱导的肝损伤中的作用
- 批准号:
10019530 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Role of chitinase-3-like-1 (Chi3l1) in acetaminophen-induced liver injury
几丁质酶 3-like-1 (Chi3l1) 在对乙酰氨基酚诱导的肝损伤中的作用
- 批准号:
10219240 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Role of gp91phox in Hepatic MF Programming and Alcohol Liver Disease
gp91phox 在肝脏 MF 编程和酒精性肝病中的作用
- 批准号:
9129373 - 财政年份:2016
- 资助金额:
$ 43.24万 - 项目类别:
Effect of Lactoferrin on Alcohol-Induced Dysbiosis and Gut Barrier Dysfunction
乳铁蛋白对酒精引起的生态失调和肠道屏障功能障碍的影响
- 批准号:
8738543 - 财政年份:2013
- 资助金额:
$ 43.24万 - 项目类别:
Effect of Lactoferrin on Alcohol-Induced Dysbiosis and Gut Barrier Dysfunction
乳铁蛋白对酒精引起的生态失调和肠道屏障功能障碍的影响
- 批准号:
8568645 - 财政年份:2013
- 资助金额:
$ 43.24万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 43.24万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 43.24万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 43.24万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 43.24万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 43.24万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 43.24万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 43.24万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 43.24万 - 项目类别: